Sign In
Buy SESN
$0.629
+0 (+0%)
At Close: Jun 06, 2023
EQUITY ALERT: Rosen Law Firm Encourages Sesen Bio, Inc. Investors with Losses to Inquire About Class Action Investigation – SESN
03:34pm, Thursday, 19'th Aug 2021
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Sesen Bio, Inc. (NASDAQ: SESN)
RADNOR, Pa., Aug. 19, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders
Lost Money in Sesen Bio, Inc.?
10:04pm, Wednesday, 18'th Aug 2021
OAKLAND, Calif.--(BUSINESS WIRE)---- $SESN #SESN--Gibbs Law Group is investigating potential legal claims on behalf Sesen Bio investors.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors
07:01pm, Wednesday, 18'th Aug 2021
LOS ANGELES--(BUSINESS WIRE)---- $SESN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on
The Law Offices of Frank R. Cruz Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors
02:53pm, Wednesday, 18'th Aug 2021
LOS ANGELES--(BUSINESS WIRE)---- $SESN #investors--The Law Offices of Frank R. Cruz Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors
Sesen Bio's Bladder Cancer Trial Wrecked By Misconduct: Stat News
01:45pm, Wednesday, 18'th Aug 2021
Sesen Bio Inc (NASDAQ: SESN) said that it was not expecting a CRL from the FDA for its bladder cancer candidate Vicineum. But the rejected filing includes several violations and investigator miscon
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sesen Bio, Inc. - SESN
05:56pm, Tuesday, 17'th Aug 2021
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sesen Bio, Inc. ("Sesen Bio" or the "Company") (NASDAQ: SESN). Such investors a
Why Sesen Bio Stock Bounced Back Sharply Today
05:15pm, Tuesday, 17'th Aug 2021
Some investors clearly believe all is not lost with the company's leading pipeline drug.
Federman & Sherwood Announces an Investigation into Sesen Bio
04:25pm, Tuesday, 17'th Aug 2021
OKLAHOMA CITY--(BUSINESS WIRE)-- #Biotechnology--Federman & Sherwood announces an investigation into Sesen Bio (NASDAQ: SESN). The complaint will allege violations of federal securities laws, Sections
Why Sesen Bio Stock Fell off a Cliff Monday
08:11pm, Monday, 16'th Aug 2021
The FDA dashes the company's hopes for its core pipeline drug...at least for now.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sesen Bio, Inc. - SESN
06:20pm, Monday, 16'th Aug 2021
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sesen Bio, Inc. ("Sesen Bio" or the "Company") (NASDAQ: SESN). Such investors are advised t
Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA
12:59pm, Monday, 16'th Aug 2021
Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.
SESN Stock: Why Sesen Bio Is Getting Slammed Today
11:49am, Monday, 16'th Aug 2021
Sesen Bio (SESN) stock is taking a beating on Monday following a letter from the U.S. Food and Drug Administration (FDA). The post SESN Stock: Why Sesen Bio Is Getting Slammed Today appeared first on
Boston, Massachusetts--(Newsfile Corp. - August 16, 2021) - Block & Leviton is investigating Sesen Bio, Inc. (NASDAQ: SESN) for potential securities law violations. Investors who have lost money in th
Why Sesen Bio Shares Are Trading Lower Today
09:20am, Monday, 16'th Aug 2021
Sesen Bio Inc (NASDAQ: SESN) is trading significantly lower Monday after the U.S. Food and Drug Administration issued a Complete Response Letter for the company's bladder cancer candidate Vicineum.
